Blinatumomab (Blincyto)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 19:14, 12 November 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Bi-specific T-cell engager (BiTE) that targets CD19. ==Diseases for which it is used== *Acute lymphocytic leukemia ==History of changes in FDA in...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Mechanism of action

Bi-specific T-cell engager (BiTE) that targets CD19.

Diseases for which it is used

Acute lymphocytic leukemia

History of changes in FDA indication

7/1/2014: Granted FDA breakthrough therapy designation "for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)."

Also known as

MT103

Retrieved from "https://hemonc.org/w/index.php?title=Blinatumomab_(Blincyto)&oldid=5626"